To develop a simple blood and urine test that we would perform before patients start their treatment to predict the risk that their bladder cancer might come back. To develop this test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer patients and follow them closely during and after treatment. This will include looking for changes in proteins and genes that might play a role in bladder cancer biology. The investigators will then compare the information obtained from the studies of blood, urine and cancer tissue between patients that are cured and those whose cancer comes back. The knowledge about these differences between patients can then potentially be used to develop a blood or urine test to tell us who has a high risk for having bladder cancer come back.
|Overal Status||Start Date||Phase||Study Type|
|Recruiting||January 21, 2014||N/A||Observational|
Primary Outcome 1 - Measure: Identify novel biomarkers for bladder cancer
Primary Outcome 1 - Time Frame: up to 5 years
- Adult patients ≥18 years old.
- Patients suspected, clinically diagnosed, or histologically diagnosed bladder cancer.
- Patients undergoing cystoscopy without cancer suspicion.
- Ability to give an informed consent.
- Patients receiving concurrent therapy for a second malignancy.
- < 18 years old.
- Inability to give an informed consent.
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: No
Name: Arna Chakravarti, MD
Role: Principal Investigator
Affiliation: The Ohio State University Cancer Center
Name: Ohio State University Comprehensive Cancer Center
Link: The Jamesline
|The Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
The Ohio State University Comprehensive Cancer Center